Skip to main content

Plus Therapeutics Value Stock - Dividend - Research Selection

Cytori therapeutics

ISIN: US72941H4002 , WKN: A2PPX6

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Cytori Therapeutics, Inc., a therapeutics company, together with its subsidiaries, develops regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for various medical conditions. Its lead drug candidate, ATI-0918, is a generic version of pegylated liposomal encapsulated doxorubicin, which is in Phase III clinical trial and used for various cancer types. The company\'s second nanomedicine drug candidate is, ATI-1123, a novel and new chemical entity, which has completed Phase I clinical trial and is a workhorse chemotherapeutic drug used for various cancers. It also sells Celution cell processing systems, StemSource cell and tissue banking systems, and surgical accessories and instrumentation to hospitals, clinics, physicians, researchers, and other customers for commercial and research purposes through a combination of a direct sales force, third-party distributors, independent sales representatives, and licensees. In addition, the company markets and sells its proprietary enzymatic reagents under the Celase and Intravase brands. It has operations in the Americas, Japan, EMEA, and the Asia Pacific. Cytori Therapeutics, Inc. was founded in 1996 and is headquartered in San Diego, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Targeted Cancer Treatment: Plus Therapeutics CEO Marc Hedrick, Live from NYSE

2023-09-19
Healthcare Edge hosted a fireside chat from the floor of the New York Stock Exchange with Marc Hedrick, M.D., President and CEO of Plus Therapeutics, Inc. (Nasdaq: PSTV). Dr. Hedrick spoke to Healthcare Edge Editor-in-Chief John Jannarone about its novel targeted radio-therapeutics treatment for central nervous system cancer using the latest technology, its future potential […]

Plus Therapeutics And 2 Other Stocks Under $2 Insiders Are Buying

2023-09-18
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Director Howard Clowes Buys 6,993 Shares of Plus Therapeutics Inc

2023-09-15
On September 13, 2023, Howard Clowes, a director at Plus Therapeutics Inc (NASDAQ:PSTV), purchased 6,993 shares of the company.

Biotech Alert: Searches spiking for these stocks today

2023-09-13
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Avalo Therapeutics, Rocket Pharmaceuticals, Acelyrin among healthcare movers

2023-09-13
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

GRAB, BIOC and PSTV among pre-market losers

2023-09-13
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Plus Therapeutics Presents Cancer Treatment Data at Conference

2023-09-11
By Daniella Parra Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company specializing in advanced radiotherapeutics for brain cancer, said it will present data from its ReSPECT-LM clinical trial at the CPRIT Innovations in Cancer Prevention and Research Conference VI. The presentation focuses on their lead radiotherapeutic, rhenium obisbemeda, for treating leptomeningeal metastases, the company […]

Why Avantax Shares Are Trading Higher By Over 27%? Here Are Other Stocks Moving In Monday's Mid-Day Session

2023-09-11
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Plus Therapeutics gets $1.9M advance payment from CPRIT

2023-09-11
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

JonesTrading Sticks to Its Buy Rating for Plus Therapeutics (PSTV)

2023-09-11
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.